With $46m, i2o Takes Up The Challenge Of Winning Approval For ITCA 650

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

The Boston biotech raises series A cash and succeeds Intarcia as the sponsor of the GLP-1 drug/device combination product for type 2 diabetes, subject of two FDA complete response letters.

Business partners hands on top of each other symbolizing companionship
i2o adds to its pipeline by acquiring Intarcia IP

Metabolic disease-focused i2O Therapeutics, Inc. is taking the baton on long-troubled GLP-1 combination product ITCA 650 from now defunct Intarcia Therapeutics, Inc. as part of a series of transactions that i20 unveiled on 28 August. The Boston-based firm also announced that former Intarcia CEO Kurt Graves will take over as i2o’s CEO, thereby bringing in Intarcia’s full pipeline, including GLP-1, amylin, glucagon and pancreatic polypeptide candidates to pair with i2o’s ionic liquids formulation technology.

Together, Graves hopes these assets, backed by a $46m series A financing also announced on 28 August, will position i2o...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.